Actively Recruiting
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
Led by Pulmovant, Inc. · Updated on 2026-04-22
20
Participants Needed
1
Research Sites
105 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
CONDITIONS
Official Title
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to provide informed consent
- Currently on inhaled treprostinil
- Diagnosed with interstitial lung disease confirmed by high-resolution CT scan showing diffuse parenchymal disease
- Diagnosed with idiopathic interstitial pneumonia, chronic hypersensitivity pneumonitis, or ILD associated with connective tissue disease with forced vital capacity less than 70% of predicted
- Confirmed pulmonary hypertension by right heart catheterization
- Able to perform a six-minute walk distance of at least 100 meters
You will not qualify if you...
- Diagnosis of pulmonary hypertension Group 1, 2, 4, or 5
- Exacerbation of underlying lung disease within 28 days before randomization
- Started pulmonary rehabilitation within 28 days before randomization
- Receiving more than 10 liters per minute of oxygen at rest at baseline
- History of intolerance, lack of efficacy, or allergy to mosliciguat or soluble guanylate cyclase stimulators or activators
- Received investigational or experimental therapy within 42 days or 5 half-lives before randomization
- Other unspecified exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC
Kissimmee, Florida, United States, 34746
Actively Recruiting
Research Team
P
Pulmovant
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here